Marksans Pharma Ltd Buyback 2022 Details

The formulation of pharmaceutical products is one of the areas of business in which Marksans Pharma is engaged. Their primary areas of focus include over-the-counter (OTC) and prescription drugs, which have a variety of applications across a variety of medical disciplines, including cancer, gastrointestinal, anti-diabetics, antibiotics, cardiology, pain management, and gynecology, to name a few.

They have created manufacturing facilities of world-class caliber by making use of cutting-edge technology, merging existing best practices, and adhering to tight regulatory compliance standards. These plants have been approved for use by reputable health authorities from throughout the world, including the US FDA, UK MHRA, Australian TGA, and others.

Their research and development capabilities include the creation of dossiers, the synthesis of chemicals, the optimization of processes, the development of formulations, the development of analytical instruments, and the execution of stability studies. They have a team of more than fifty highly qualified scientists who are working on the formulation of novel pharmaceuticals and the development of new methods for analytical research.

They are skilled in everything from research on a laboratory basis to scaling up a pilot operation, from commercializing a product for large-scale manufacturing to marketing it on a global scale.

The company rose to prominence on a global platform in a comparatively short amount of time, and it has lofty goals for the continued growth and expansion of its operations on a global scale in the future. The formulation of pharmaceutical products is one of the areas of business in which Marksans Pharma is engaged. Their primary areas of focus include over-the-counter (OTC) and prescription drugs, which have a variety of applications across a variety of medical disciplines, including cancer, gastrointestinal, anti-diabetics, antibiotics, cardiology, pain management, and gynecology, to name a few.

They have established world-class production facilities by making use of cutting-edge technology, merging best practices, and adhering to tight regulatory compliances. These plants have been approved for use by reputable health authorities from throughout the world, including the US FDA, UK MHRA, Australian TGA, and others.

Their research and development capabilities include the creation of dossiers, the synthesis of chemicals, the optimization of processes, the development of formulations, the development of analytical instruments, and the execution of stability studies. They have a team of more than fifty highly qualified scientists who are working on the formulation of novel pharmaceuticals and the development of new methods for analytical research.

They are skilled in every aspect of the process, from preliminary research in the lab to the scaling up of a pilot operation, from the commercialization of the product for large-scale manufacturing to marketing on a global scale.

The company rose to prominence on a global platform in a comparatively short amount of time, and it has lofty goals for the continued growth and expansion of its operations on a global scale in the future.

Marksans Pharma Buyback 2022 Date & Details

Buyback Open Date15-Jul-2022
Buyback Close Date14-Jun-2023
Buyback Price60 Rs
CMP49.45 Rs
Issue Size60 Crores
Issue TypeOpen Market
Face value1
Listing AtNSE,BSE

Information about Buyback

At its meeting on July 8, 2022, the board of directors of Marksans Pharma considered and approved the proposal for the buyback of fully paid-up equity shares with a face value of Rs. 1 and a maximum of 1,00,00,000 equity shares (representing 8.78 percent of the total number of equity shares in the paid-up equity share capital of the Company) for an aggregate sum of Rs. 60 Cr. Only.

Buy Back Offer Deal

Buyback Type:Open Market
Buyback Offer Amount:₹ 60 Cr.
Date of Board Meeting approving the proposal:Jul 08 2022
Date of Public Announcement:Jul 08 2022
Buyback Offer Size:8.78%
Buyback Number of Shares:1,00,00,000
FV:1
Buyback Price:₹ 60 Per Equity Share

Necessity of the Issue

The following justifies the buyback’s undertaking:

  1. The buyback will assist the company in paying its shareholders any excess cash.
  2. The Buyback is often anticipated to boost return on equity via the distribution of cash and increase profits per share through the decrease in the Company’s equity base, resulting in a long-term rise in the value of the shareholders.

How to Take Part in the Buyback?

With this share buyback strategy, the corporation will acquire stocks from current shareholders of the company on the open market.

Example: “Marksans Pharma” announces a share buyback plan up to Rs. 60, which implies the business will acquire shares of “Marksans Pharma” on the open market at a price that does not go over Rs. 60 per share.

Scenario 1: The corporation will place a buy order at the current market price and acquire shares if the share price falls below Rs. 60.

Scenario 2: If the share price is more than 60 rupees, the firm will only place a purchase order at 60 rupees, and if someone is willing to sell for 60 rupees or less, only the company will get the shares back.

Photo of author

Dharam

Dharam Nath Jha is a financial content writer, blogger and SEO specialist. He has a keen interest in researching about financial topics like the stock market, mutual funds etc and developing quality content. He is developing content for the past 3 years and during this period he has worked for 8 firms.

Leave a Comment

FREE Investment and Trading Tips